Oxford BioMedica Combines With Mayo Clinic On Gene Therapy For Glaucoma
This article was originally published in The Pink Sheet Daily
Executive Summary
Oxford BioMedica and U.S. researchers at the Mayo Clinic are to use the company's lentivirus vector to deliver two prostaglandin-related genes into the front of the eye to alleviate glaucoma.
You may also be interested in...
Amsterdam Molecular Therapeutics Ends Glybera Development, Halves Workforce
AMT halves head count and restructures following second rejection by European regulators of its potential gene therapy, Glybera.
Imagen's Ophthalmology In-Licensing Strategy Attracts $40M Series A
With a plan to take advantage of scientific advances suggesting that compounds for cancer and other diseases may have facility in the eye, Imagen will seek ideal candidates for dry AMD.
Belgium's Amakem Raises €18 million In Europe's Largest Series A So Far In 2011
Belgian start-up raises record-breaking €18 million A round to take rho kinase inhibitor glaucoma candidate to clinical proof-of-concept.